Novel CHK1 inhibitor MU380 exhibits significant single-agent activity in TP53-mutated chronic lymphocytic leukemia cells

Introduction of small-molecule inhibitors of B-cell receptor signaling and BCL2 protein significantly improves therapeutic options in chronic lymphocytic leukemia. However, some patients suffer from adverse effects mandating treatment discontinuation, and cases with TP53 defects more frequently expe...

Disgrifiad llawn

Manylion Llyfryddiaeth

Prif Awduron:	Miroslav Boudny, Jana Zemanova, Prashant Khirsariya, Marek Borsky, Jan Verner, Jana Cerna, Alexandra Oltova, Vaclav Seda, Marek Mraz, Josef Jaros, Zuzana Jaskova, Michaela Spunarova, Yvona Brychtova, Karel Soucek, Stanislav Drapela, Marie Kasparkova, Jiri Mayer, Kamil Paruch, Martin Trbusek
Fformat:	Artigo
Iaith:	Inglês
Cyhoeddwyd:	Ferrata Storti Foundation 2019-12-01
Cyfres:	Haematologica
Mynediad Ar-lein:	https://haematologica.org/article/view/9168
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!